Samarth Kulkarni - Oct 13, 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Oct 13, 2023
Transactions value $
$0
Form type
4
Date filed
10/17/2023, 05:51 PM
Previous filing
Jun 23, 2023
Next filing
Jan 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +52.5K $0.00 52.5K Oct 13, 2023 Common Shares 52.5K $44.31 Direct F1
transaction CRSP Restricted Stock Unit Award $0 +25K $0.00 25K Oct 13, 2023 Common Shares 25K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on October 13, 2023 with respect to 52,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.